XTX Topco Ltd Sells 3,644 Shares of TransMedics Group, Inc. $TMDX

XTX Topco Ltd lessened its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 18.8% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,698 shares of the company's stock after selling 3,644 shares during the quarter. XTX Topco Ltd's holdings in TransMedics Group were worth $2,104,000 at the end of the most recent reporting period.

• Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May

Other large investors have also recently made changes to their positions in the company. Opal Wealth Advisors LLC bought a new stake in TransMedics Group during the second quarter valued at about $26,000. Smartleaf Asset Management LLC lifted its position in shares of TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company's stock valued at $30,000 after buying an additional 135 shares during the last quarter. Quarry LP boosted its holdings in shares of TransMedics Group by 88.5% in the 1st quarter. Quarry LP now owns 592 shares of the company's stock valued at $40,000 after buying an additional 278 shares in the last quarter. Sound Income Strategies LLC purchased a new position in shares of TransMedics Group in the 2nd quarter worth approximately $48,000. Finally, CWM LLC raised its stake in shares of TransMedics Group by 20.1% during the 1st quarter. CWM LLC now owns 925 shares of the company's stock worth $62,000 after acquiring an additional 155 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

TransMedics Group Stock Down 0.2%

TMDX stock opened at $145.75 on Thursday. The company has a market capitalization of $4.98 billion, a P/E ratio of 59.01 and a beta of 2.05. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $148.50. The firm's fifty day simple moving average is $121.71 and its 200-day simple moving average is $121.82. The company has a debt-to-equity ratio of 1.43, a current ratio of 7.69 and a quick ratio of 7.13.

• 3 Medical Technology Stocks Outperforming in 2025

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Wednesday, October 29th. The company reported $0.66 EPS for the quarter, topping analysts' consensus estimates of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The firm had revenue of $143.82 million for the quarter, compared to the consensus estimate of $145.33 million. During the same quarter in the prior year, the business earned $0.12 earnings per share. The company's revenue was up 32.2% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TMDX. Morgan Stanley lifted their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Piper Sandler dropped their price target on TransMedics Group from $145.00 to $140.00 and set an "overweight" rating on the stock in a research note on Thursday, October 30th. Evercore ISI began coverage on shares of TransMedics Group in a research report on Tuesday, September 16th. They issued an "outperform" rating and a $155.00 price objective for the company. Jefferies Financial Group began coverage on shares of TransMedics Group in a research note on Monday, October 13th. They issued a "buy" rating and a $145.00 target price for the company. Finally, Stifel Nicolaus began coverage on shares of TransMedics Group in a research note on Thursday, September 4th. They set a "hold" rating and a $115.00 price target on the stock. Seven equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat.com, TransMedics Group has an average rating of "Moderate Buy" and an average price target of $131.80.

• 3 High-Growth Stocks Traders Love and Investors Should Watch

Read Our Latest Analysis on TMDX

Insider Buying and Selling

In related news, Director Edward M. Basile sold 4,142 shares of TransMedics Group stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total value of $540,323.90. Following the sale, the director owned 2,866 shares of the company's stock, valued at approximately $373,869.70. This trade represents a 59.10% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Anil P. Ranganath sold 3,000 shares of the business's stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the completion of the sale, the insider directly owned 13,955 shares of the company's stock, valued at approximately $2,026,545.10. The trade was a 17.69% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 7.00% of the stock is owned by insiders.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Featured Stories

• Five stocks we like better than TransMedics Group
• Dividend Capture Strategy: What You Need to Know
• Tesla Just Got Called a “Must Own” Stock—Here’s Why
• Consumer Staples Stocks, Explained
• Why Gold Loves Trump as Much as Trump Loves Gold
• Breakout Stocks: What They Are and How to Identify Them
• Google's Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage

Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in TransMedics Group Right Now?

Before you consider TransMedics Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.

While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here